Renaissance Technologies
CATX icon

Renaissance Technologies’s Perspective Therapeutics CATX Stock Holding History

Renaissance Technologies’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Buy
+59,133
New +$223K ﹤0.01% 2879
2026
Q1 		– Sell
-352,493
Closed -$969K – 3293
2025
Q4 		$969K Buy
+352,493
New +$1.01M ﹤0.01% 2300
2025
Q2 		– Sell
-163,460
Closed -$348K – 3582
2025
Q1 		$348K Buy
+163,460
New +$491K ﹤0.01% 2870
2024
Q3 		– Sell
-61,660
Closed -$615K – 3552
2024
Q2 		$615K Buy
61,660
+58,485
+1,842% +$846K ﹤0.01% 2599
2024
Q1 		$38K Sell
3,175
-27,500
-90% -$234K ﹤0.01% 3522
2023
Q4 		$123K Sell
30,675
-6,090
-17% -$17.1K ﹤0.01% 3252
2023
Q3 		$101K Sell
36,765
-6,928
-16% -$32.3K ﹤0.01% 3239
2023
Q2 		$292K Buy
43,693
+2,040
+5% +$12.4K ﹤0.01% 3136
2023
Q1 		$266K Buy
41,653
+3,740
+10% +$15.3K ﹤0.01% 3166
2022
Q4 		$94K Buy
37,913
+700
+2% +$2.31K ﹤0.01% 3640
2022
Q3 		$86K Sell
37,213
-496
-1% -$1.7K ﹤0.01% 3639
2022
Q2 		$117K Sell
37,709
-4,023
-10% -$12.3K ﹤0.01% 3807
2022
Q1 		$151K Sell
41,732
-56,359
-57% -$206K ﹤0.01% 3716
2021
Q4 		$380K Sell
98,091
-21,272
-18% -$113K ﹤0.01% 3226
2021
Q3 		$753K Sell
119,363
-138,667
-54% -$945K ﹤0.01% 2700
2021
Q2 		$2.06M Sell
258,030
-67,993
-21% -$595K ﹤0.01% 2244
2021
Q1 		$3.55M Buy
326,023
+191,170
+142% +$2.89M ﹤0.01% 1861
2020
Q4 		$607K Buy
134,853
+83,783
+164% +$370K ﹤0.01% 2736
2020
Q3 		$298K Sell
51,070
-56,735
-53% -$370K ﹤0.01% 2999
2020
Q2 		$599K Buy
107,805
+39,389
+58% +$253K ﹤0.01% 2805
2020
Q1 		$363K Buy
68,416
+43,761
+177% +$330K ﹤0.01% 2902
2019
Q4 		$154K Buy
+24,655
New +$108K ﹤0.01% 3241

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Renaissance Technologies's CATX Position: Q2 2026 in Review

Renaissance Technologies opened a new position in Perspective Therapeutics (CATX) in Q2 2026: 59,133 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #2879 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in CATX as recently as Q4 2025.

Renaissance Technologies first reported a position in CATX in Q4 2019 and has held it in 22 quarters since. The position peaked at $3.55M in Q1 2021. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Renaissance Technologies held 59,133 shares of Perspective Therapeutics worth $202K as of Q2 2026.
  • Perspective Therapeutics was a new Renaissance Technologies position in Q2 2026.
  • Perspective Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2879 holding.
  • Renaissance Technologies first reported a position in Perspective Therapeutics in Q4 2019 and has held it in 22 quarters since.
  • Renaissance Technologies's Perspective Therapeutics position peaked at $3.55M in Q1 2021.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.